公开(公告)号：EP2258722A3

公开(公告)日：2011-10-12

申请号：EP10010388.6

申请日：2000-09-05

申请人： Amgen, Inc

发明人： Thomason, Arlen ,  Liu, Benxian

IPC分类号： C07K16/24 ,  G01N33/53

CPC分类号： C07K14/50 ,  A61K38/00 ,  C07K2319/30 ,  C12N2310/111 ,  G01N2333/50

摘要： The present invention provides antibodies to Fibroblast Growth Factor-like (FGF-like) polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides

公开(公告)号：EP2189475A3

公开(公告)日：2010-11-17

申请号：EP09002072.8

申请日：2000-09-05

申请人： Amgen Inc.

发明人： Thomason, Arlen ,  Liu, Benxian

IPC分类号： C07K14/50 ,  C12N15/19

CPC分类号： C07K14/50 ,  A61K38/00 ,  C07K2319/30 ,  C12N2310/111 ,  G01N2333/50

摘要： The present invention provides Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.

公开(公告)号：EP1790983A4

公开(公告)日：2008-05-07

申请号：EP05768836

申请日：2005-07-29

申请人： JAPAN TOBACCO INC ,  MATSURA YOSHIHARU ,  LIM CHANG KWANG

发明人： MATSUURA YOSHIHARU ,  LIM CHANG KWANG ,  KOMODA YASUMASA ,  SUZUKI KENSUKE

IPC分类号： G01N33/576 ,  A61K45/00 ,  A61P1/16 ,  A61P31/12 ,  C12N15/09 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  G01N33/566 ,  G01N33/74

CPC分类号： G01N33/5767 ,  G01N2333/18 ,  G01N2333/50 ,  G01N2500/02

摘要： A screening method and an identification method for a compound which prevents cells from the infection with hepatitis C virus (HCV) comprising measuring the affinity with a fibroblast growth factor receptor (FGFR) or the ability to block the binding to HCV and thus selecting or judging a test compound.

公开(公告)号：EP1599577A2

公开(公告)日：2005-11-30

申请号：EP04715174.1

申请日：2004-02-26

申请人： THE UAB RESEARCH FOUNDATION

发明人： QU, Zhican ,  KERN, Frances

IPC分类号： C12N1/00

CPC分类号： G01N33/5088 ,  A01K67/0271 ,  A01K2227/105 ,  A01K2267/0331 ,  G01N2333/475 ,  G01N2333/50

摘要： Expression of VEGF correlates with clinically aggressive, tamoxifen resistant metastatic breast cancers. To assess the role of VEGF expression on breast cancer growth, metastasis and development of anti-estrogen resistance, and desmoplasia an ER-positive, several MCF-7-derived cell lines, designated C9V, were engineered to express VEGF in a doxycycline-regulated manner. C9V cells were introduced into a athymic nude mouse to produce a xenograft model of breast cancer. Expression of VEGF in xenografts increased neoangiogenesis, enhanced tumor growth, stimulated a tamoxifen resistant phenotype, increased metastatic potential and induced a desmoplastic response. These results suggest that inhibition of VEGF expression or action will be effective in the treatment of breast cancer. In addition, inhibition of VEGF expression or action with inhibition of estrogen expression or action may also be effective.

公开(公告)号：EP1560025A2

公开(公告)日：2005-08-03

申请号：EP04022939.5

申请日：2004-09-27

申请人： F. Hoffmann-La Roche AG

发明人： Kochan, Jarema Peter ,  Martin, Mitchell Lee ,  Rosinski, James Andrew

IPC分类号： G01N33/68 ,  C07K14/47

CPC分类号： G01N33/6893 ,  C07K14/4713 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/74 ,  G01N2333/50 ,  G01N2333/775 ,  G01N2500/04

摘要： The present invention provides polypeptides which are correlated with pre-diabetes, diabetes or susceptibility to diabetes which can be used as markers for diagnosis of pre-diabetes, diabetes or a susceptibility or predisposition to develop diabetes. The invention also provides methods for the diagnosis of pre-diabetes, diabetes and/or the susceptibility to diabetes by obtaining a biological sample and detecting and/or measuring the increase of one or more polypeptides as disclosed herein. Screening methods relating to agonists and antagonists of the specific polypeptides disclosed herein are provided. Antibodies may also be raised against these polypeptide markers for the detection and/or treatment of diabetes. Proteins, protein fragments or peptides can be used for the treatment of diabetes or pre-diabetes.

摘要翻译： 本发明提供与糖尿病前期，糖尿病或糖尿病易感性相关的多肽，其可用作诊断前期糖尿病，糖尿病或发生糖尿病的易感性或易感性的标志物。 本发明还提供了通过获得生物样品来诊断前期糖尿病，糖尿病和/或对糖尿病易感性的方法，并且检测和/或测量本文所公开的一种或多种多肽的增加。 提供了与本文公开的具体多肽的激动剂和拮抗剂相关的筛选方法。 也可以针对这些多肽标记物提出抗体用于检测和/或治疗糖尿病。 蛋白质，蛋白质片段或肽可用于治疗糖尿病或前期糖尿病。

公开(公告)号：EP0836380A4

公开(公告)日：1999-03-31

申请号：EP96917641

申请日：1996-06-12

申请人： YEDA RES & DEV

发明人： YAYON AVNER

IPC分类号： C12N15/09 ,  A01K67/027 ,  A61K9/22 ,  A61K35/32 ,  A61K38/00 ,  A61K38/22 ,  A61K39/395 ,  A61K45/00 ,  A61L27/00 ,  A61P5/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/50 ,  C07K14/715 ,  C07K16/00 ,  C07K16/24 ,  C07K16/28 ,  C12N5/00 ,  C12N5/06 ,  C12P21/08 ,  C12Q1/02 ,  G01N33/53 ,  G01N33/558 ,  G01N33/566 ,  G01N33/569 ,  G01N33/68 ,  G01N33/74 ,  A01K67/00 ,  A61K39/00 ,  C12N15/00

CPC分类号： G01N33/566 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/50 ,  C07K16/2863 ,  G01N33/53 ,  G01N33/56966 ,  G01N33/6887 ,  G01N33/74 ,  G01N2333/50 ,  G01N2333/9121

摘要： The present invention concerns fibroblast growth factor receptor 3 (FGFR3) as a novel marker for mesenchymal skeletal progenitor cells. By utilizing this novel marker it was possible both to identify and locate mesenchymal skeletal progenitor cells in a tissue, as well as to obtain a substantially pure culture of such cells. The pure culture of the mesenchymal skeletal progenitor cells may be used, optionally after various manipulations ex vivo, as an active ingredient in pharmaceutical compositions or implants for the purpose of bone and/or cartilage repair. FGFR3 may also be used as a marker for the identification and the localization of cartilage- and bone-derived tumors. Agents capable of binding to FGFR3 may also be used for targeting cytotoxic agents to cartillage- and bone-derived tumors.The present invention concerns fibroblast growth factor receptor 3 (FGFR3) as a novel marker for mesenchymal skeletal progenitor cells. By utilizing this novel marker it was possible both to identify and locate mesenchymal skeletal progenitor cells in a tissue, as well as to obtain a substantially pure culture of such cells. The pure culture of the mesenchymal skeletal progenitor cells may be used, optionally after various manipulations ex vivo, as an active ingredient in pharmaceutical compositions or implants for the purpose of bone and/or cartilage repair. FGFR3 may also be used as a marker for the identification and the localization of cartilage- and bone-derived tumors. Agents capable of binding to FGFR3 may also be used for targeting cytotoxic agents to cartillage- and bone-derived tumors.

公开(公告)号：EP0387777A2

公开(公告)日：1990-09-19

申请号：EP90104706.8

申请日：1990-03-13

申请人： Takeda Chemical Industries, Ltd.

发明人： Sato, Yuji ,  Friesen, Henry,G.

IPC分类号： G01N33/68

CPC分类号： G01N33/74 ,  G01N33/57484 ,  G01N2333/50

摘要： A sandwich method, in which an antibody coupled to a carrier, a sample and heparin labeled with a labeling agent, brings about a high sensitivity for detecting and/or measuring FGF, and the method is usable for diagnosis of tumor.

摘要翻译： 其中与载体偶联的抗体，用标记试剂标记的样品和肝素的夹心方法对于检测和/或测量FGF具有高灵敏度，并且该方法可用于诊断肿瘤。

公开(公告)号：EP2824181B1

公开(公告)日：2018-11-14

申请号：EP13757006.5

申请日：2013-03-07

申请人： Astellas Pharma Inc.

发明人： SUZUKI, Atsushi ,  ASAUMI, Makoto ,  TSUNOYAMA, Kazuhisa ,  NISHIMURA, Kouichi ,  MORINAKA, Akifumi ,  YAMAUCHI, Tomohiro ,  YOSHINO, Masayasu ,  YOSHIZAKI, Hiroaki

IPC分类号： C12Q1/6886

CPC分类号： A61K31/506 ,  A61K31/4439 ,  A61K31/496 ,  C07K14/47 ,  C07K14/71 ,  C07K2319/00 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57423 ,  G01N33/74 ,  G01N2333/50

摘要： [Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. [Means for Solution] The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.

公开(公告)号：EP3363347A1

公开(公告)日：2018-08-22

申请号：EP16854695.0

申请日：2016-10-14

申请人： Universidad De Chile

发明人： TORO CABRERA, Luis Alejandro ,  MICHEA ACEVEDO, Luis Fernando

IPC分类号： A61B5/00

CPC分类号： A61B5/201 ,  A61B5/00 ,  G01N33/493 ,  G01N33/5038 ,  G01N33/5091 ,  G01N33/746 ,  G01N2333/50 ,  G01N2800/347 ,  G01N2800/56 ,  G01N2800/60

摘要： The invention relates to an ex vivo method for the early detection of acute kidney injury in critical patients, comprising the use of measurements of fibroblast growth factor 23 (FGF23), klotho (KL) and erythropoietin (EPO) as biomarkers, where such measurements are obtained from a venous blood sample or urine, and allow the following factors to be calculated: 1 = ([FGF23]p x [EPO]p); 2 = ([FGF23]p / [Klotho]p); 3 = ([EPO]p) / [Klotho]p); 4 = (([FGF23]p x [EPO]p) / [Klotho]p); where [X]p is the measurement of the plasma level of X and X is selected from fibroblast growth factor 23 (FGF23), klotho (KL) and erythropoietin (EPO). If the value of the indicator 1, 2, 3, 4 or two or more thereof, is higher than, or equal to, a cut-off point (10 U) which allows identification of patients with and without AKL with a high level of sensitivity/specificity, then a high probability of presence/development of AKI is confirmed, and measures can be taken for patients with AKI. If the indicator value 1, 2, 3, 4 or two or more thereof is lower than the previously mentioned cut-off point, then the probability of presence/development of AKI is low and standard treatment can be carried out, that is, with use of endovenous solutions, prevention of the use of nephrotoxins, use of renal replacement therapy in severe AKI, inter alia.

公开(公告)号：EP2895866B1

公开(公告)日：2018-05-30

申请号：EP13713175.1

申请日：2013-03-28

申请人： Roche Diagnostics GmbH ,  F. Hoffmann-La Roche AG

发明人： BLOCK, Dirk ,  MASSON, Serge ,  WIENHUES-THELEN, Ursula-Henrike ,  ZAUGG, Christian ,  LATINI, Roberto

IPC分类号： G01N33/68

CPC分类号： G01N33/6887 ,  A61B5/055 ,  A61B8/0883 ,  G01N33/82 ,  G01N2333/4703 ,  G01N2333/4706 ,  G01N2333/4712 ,  G01N2333/50 ,  G01N2333/78 ,  G01N2800/32 ,  G01N2800/329 ,  G01N2800/50

摘要： The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.